News MSD said to have pulled back from Revolution Meds deal Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.
News COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.
News Introducing the Sunday Times Tech 100: Life sciences part 1 The 2026 Sunday Times Tech 100 list includes 23 companies in the life sciences arena, and in this article we focus on five in the software category.
News Digital osteoarthritis, bulimia tools backed for NHS use Guidance in the UK has cleared the way for NHS use of digital health technologies for people with osteoarthritis and eating disorder bulimia.
News Sanofi plans amlitelimab dermatitis filing after new readout Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.
News Corxel's raises $287m for obesity drug, and other financings Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.